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ABSTRACT: Sequence-dependent thermodynamic quantities for the antiviral agent netropsin and a related 
bis(N-methylimidazole) dipeptide, lexitropsin, have been determined by DNase I footprinting techniques. 
The primary data  a re  autoradiographic spot intensities derived from 10 footprinting experiments carried 
out in the temperature range 0-45 OC. After exclusion effects due to  overlapped drug sites on D N A  and 
redistribution phenomena associated with the enzyme were accounted for, sequence-dependent binding 
constants for the two ligands were calculated. Our approach does not require an independent determination 
of the free drug concentration, which is calculated, with individual site binding constants, by using only 
footprinting data. The temperature dependence of the binding constants for netropsin implied that the binding 
enthalpies for all the sites but one on a 139 base pair restriction fragment of pBR 322 D N A  are exothermic. 
Their values roughly correlate with the free energies of binding, which are smaller for sites including a 5’-TA-3’ 
sequence. The binding enthalpies for the lexitropsin to all its sites were exothermic and more negative than 
those of netropsin. This may be due to  the greater ability of the lexitropsin, when compared to  netropsin, 
to form hydrogen bonds with sites on DNA.  The binding constants of the lexitropsin toward its GC interaction 
sequences were much lower than those of netropsin, as can be explained by the reduced charge of the former 
ligand. Although it is difficult to determine the specific origin of the thermodynamic effects measured, 
comparison between netropsin and the lexitropsin suggests that  the degree of solvation in the minor groove 
of D N A  may be a factor influencing the entropy of the binding process. 
I n  the typical footprinting experiment, a cleavage agent is 
used to partially digest a DNA fragment in the presence and 
absence of DNA-binding ligand (Galas & Schmitz, 1978; 
Schmitz & Galas, 1979; Van Dyke et al., 1982; Lane et al., 
1983; Scamrov & Beabealashvilli, 1983; Fox & Waring, 
1984). If the ligand is able to inhibit cleavage at the site of 
binding, the locations of these sites appear as omissions or 
“footprints” on a DNA sequencing autoradiogram. Aside from 
simply revealing the sites of binding, the footprinting exper- 
iment has the potential of generating individual site binding 
isotherms. This information, which cannot be obtained by any 
other experimental technique, allows the determination of 
ligand binding constants as a function of sequence on natural 
DNA molecules. Ackers and co-workers (Brenowitz et al., 
1986a,b; Senear, et a]., 1986), as well as others (Carey, 1988; 
Letovsky & Dynen, 1989), showed that footprinting data could 
be used to measure the binding constants of proteins bound 
to DNA. Although the low sequence specificity of drugs and 
other small ligands leads to complications not found in foot- 
printing experiments involving proteins, it has been demon- 
strated that quantitative footprinting analysis can be used to 
determine the binding constants of the antiviral agent netropsin 
(1; Figure 1 )  bound to DNA (Ward et al., 1987, 1988a; Fish 
et al., 1988). Additional studies revealed the relationships 
between drug-DNA and probe-DNA equilibria and the 
manner in which the probe is able to report the occupancy of 
a binding site by a drug molecule in the quantitative foot- 
printing experiment (Ward et al., 1988b; Dabrowiak et al., 
1989a,b; Dabrowiak & Goodisman, 1989, 1990; Rehfuss et 
al., 1990). In this report we show that it is possible to obtain 
a full thermodynamic profile (AGO, AH”,  and AS”)  of drug 
binding as a function of sequence on polymeric DNA by using 
only footprinting data. 
The antiviral agent netropsin (1) binds within the minor 
groove of DNA to sites of type (AeT),. The specificity of the 
agent appears to be related to the fact that the floor of the 
minor groove in AT-ri’ch regions of DNA is relatively flat and 
featureless (Kopka et al., 1985; Coll et al., 1989). This allows 
deep penetration of the drug into the minor groove, producing 
close van der Waals contacts and hydrogen bonds between the 
agent and DNA. An additional factor influencing specificity 
of netropsin is the fact that the minor groove in AT-rich 
regions is charged negatively (Lavery & Pullman, 1985). 
Since the drug is a dication, electrostatic interactions may also 
play a role in the AT specificity of the antiviral agent. 
The sequence-reading peptide or lexitropsin (2) was designed 
to target GC-rich regions of DNA. Previous footprinting 
studies with the compound (Kissinger et al., 1987; Dabrowiak 
et al., 1989a) revealed that it exhibits a high affinity for sites 
possessing guanine and cytosine in the binding sequence. By 
analogy with the single-crystal X-ray analyses of netropsin and 
distamycin bound to small segments of DNA (Kopka et al., 
1985; Coll et al., 1989) and from N M R  and nuclear Over- 
hauser effect (NOE)’ evidence (Lee et al., 1988), the pref- 
erence of 2 for GC-rich sites was rationalized in terms of its 
ability to accept hydrogen bonds, through the imidazole ni- 
trogens, from the 2-amino group of guanine located in the 
minor groove of DNA. This ability, and the ligand’s reduced 
cationic charge, are very likely the reasons for enhanced 
binding of 2 at GC-rich sites. 
MATERIALS AND METHODS 
Quantitative footprinting studies involving 1 and 2, the latter 
a generous gift from J. W. Lown, University of Alberta, were 
carried out with DNase I (Ward et al., 1988a). The restriction 
fragment, a HindIII/NciI 139 base pair (bp) cleavage product 
‘We acknowledge the American Cancer Society, Grant NP-681, for 
support of this research. ’ Abbreviations: NOE, nuclear Overhauser effect; bp, base pairs. 
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FIGURE 1 : Structures of netropsin (1) and the sequence reading peptide 
lexitropsin (2) and the HindlII/Ncil restriction fragment from 
pBR-322 DNA. 
from pBR 322 DNA, was singly end-labeled on its noncoding 
strand a t  position 33 by using [cv3*P]ATP in the presence of 
reverse transcriptase (Lown et al., 1986). The footprinting 
experiments were conducted in a total volume of 8 pL in the 
buffer 37.5 mM Tris-HC1, 8 mM MgCI2, 2 mM CaCI,, pH 
7.5, containing 193 pM bp of sonicated calf thymus DNA, - 1 p M  labeled fragment, -0.1--0.01 p M  DNase I, and 
various concentrations of drug. The amount of DNase I 
necessary to cleave 20-30% of the labeled fragment (70-80% 
uncut) was determined by carrying out a series of calibration 
experiments in the absence of drug a t  various temperatures. 
After electrophoresis in a 12% denaturing polyacrylamide gel 
and brief autoradiography to locate the full-length band, the 
section of the gel containing the band was excised and sub- 
jected to scintillation counting. The amount of cleavage as 
determined by counting and also by scanning of the autora- 
diogram with a microdensitometer was less than -30% (single 
hit regime). The footprinting reactions for each ligand were 
carried out a t  0, 15, 25, 37, and 45 "C in a buffer medium 
containing 37 pM Tris-HCI a t  pH 7.5 for 10 min. The re- 
actions for lexitropsin were carried out at  the 16 different drug 
concentrations shown at  the top of Figure 2. While the 
netropsin experiments at  0, 15, 25, and 45 "C were carried 
out in this study, the data obtained a t  37 "C for the antiviral 
agent are those collected and analyzed in an earlier report 
(Ward et al., 1988a). 
Microdensitometric scanning of the data (Dabrowiak et al., 
1986) showed that the total amount of cleavage on the 139-mer 
remained constant as drug was added to the system. After 
minor corrections of the density data for gel loading errors, 
which were C IO%, plots showing the behavior of the intensity 
of each individual band on the autoradiogram as a function 
of total drug concentration, termed footprinting plots, were 
constructed for each temperature studied. These plots formed 
the basis of the analysis (Dabrowiak & Goodisman, 1989, 
1 990). 
For the calculations on netropsin, we used spot intensities 
measured for sites 48, 49, 50-55, 58, 59, 62-67, 83 ,87, 89, 
90, 96, 102, and 106 (23 sites). Eight of these were (see below) 
enhancement sites; the sites showing drug binding were 48, 
50, 51, 53-55, 58, 59, 62, 63, 87, 89, and 90. Intensities for 
nine drug concentrations in the range 1-10 p M  as well as an 
experiment at  zero drug concentration were used for the digests 
at  0, 15, 25, and 45 OC. This gave rise to 230 intensities, which 
were used for each temperature. The footprinting analysis a t  
37 "C consisted of a slightly larger data set involving 256 
intensities (Ward et al., 1988a). In the case of the lexitropsin, 
22 sites were monitored: 59, 63, 65-67, 73, 76, 77, 79, 80, 
83, 87, 94, 96, 106, 108, 112, 120, 124, 126, 133 and 138, 
including 8 for the enhancements. Sites showing drug binding 
were as follows: 65-67, 76, 77, 79, 80, 83, 94, 96, 106, 108, 
1 12, 120, 124 and 126. Intensities for nine drug concentrations 
in the range 0-23 p M  were used. This gave rise to 198 in- 
tensities used in the minimization. 
In order to examine only the earliest loading events on the 
restriction fragment and thus minimize any possible drug-drug 
cooperativity effects that might be present, only the low drug 
concentrations were used in the analysis. The concentrations 
employed were determined by noting the level of added drug 
for which the strong sites begin to accept ligand, but the weak 
sites do not experience binding. In the case of netropsin, this 
concentration corresponded to - 10 pM drug. For the lexi- 
tropsin used in the study, only four distinct regions of inhibition 
were observed. Since a clear distinction between their "strong" 
and "weak" binding character could not be made, Le., their 
respective values of Ki were more similar in magnitude than 
were the "strong" and "weak" binding domains of netropsin, 
a decision was made to include concentrations in the range 
0-23 pM. Although this allowed access to only the beginning 
of the titration curves for the weaker sites, it provided sufficient 
data to determine their binding constants. This is because the 
footprinting plot, after correction for the mass action effect 
associated with DNase I, can be described by a single pa- 
rameter, the binding constant. Thus, any part of the curve 
suffices to determine the binding constant. 
RESULTS 
The footprinting plots showing the cleavage intensity as a 
function of drug concentration for either drug were of three 
types. Within a binding site DNase I cleavage decreased as 
drug was added to the system. This classic footprinting 
phenomenon can be seen for lexitropsin (2) at positions 63-72, 
76-84, 106-1 14, and 119-127 of Figure 2. At numerous sites 
between drug binding sites the cleavage rate was found to 
increase as drug was added to the system. For lexitropsin (2), 
these increases can be seen a t  positions 85-1 IO and a t  other 
sites on the 139-mer (Figure 2). For certain positions, foot- 
printing plots were observed to increase a t  low drug concen- 
tration and later, at  high drug concentration, decrease. These 
positions, associated with secondary drug binding sites, were 
not addressed in this study. 
DISCUSSION 
Model Used To Analyze the Footprinting Data. The gen- 
eral approach for calculating binding constants from foot- 
printing data has been earlier described (Ward et al., 1988a; 
Dabrowiak & Goodisman, 1989, 1990). Briefly, the autora- 
diographic spot intensity for a particular cleavage product is 
proportional to the cleavage rate a t  the relevant site, ( ra te) ,  
which is given by expression I .  In expression 1, k :  is the 
(1) 
cleavage rate constant a t  the site, [DNase IIi is the effective 
concentration of enzyme at  the site, and vi is the fraction of 
the DNA fragments that have the site blocked by drug. With 
increasing drug concentration, vi increases for all sites that can 
be blocked by bound drug. Drug binding to certain sites on 
(rate)i = k'JDNase 1Ii(1 - vi)  
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partial sequence of FIGURE 2: Results of DNase I footprinting experiments with lexitropsin (2) interacting with the 139-mer at 25 OC. A - 
the noncoding strand of the restriction fragment and position numbers are shown on the left margin of the figure. See Figure 1 for thecomplete 
sequence. 
a fragment causes an increasing fraction of DNA to be un- 
available to the enzyme, making the effective concentration 
of DNase I increase at  all other DNA sites. Earlier studies 
involving netropsin and the intercalating anticancer drug ac- 
tinomycin D (Ward et al., 1988b) showed that increases in 
cleavage are proportional to the amount of DNA blocked by 
drug. This mass action effect means a footprinting plot is not 
the true isotherm for the site. Thus, the value of [DNase I I i  
in expression 1 is taken proportional to (1 - acb)-', where cb 
is the concentration of bound drug and CY is a constant de- 
scribing the enhancement, related to the fraction of sites that 
can be blocked by drug from cleavage by DNase I .  The value 
of a is found along with the drug binding constants in the 
minimization (see below). 
The relationship between the spot intensity associated with 
any oligonucleotide fragment produced in the digest, Ii, taking 
into account the mass action effect associated with DNase I ,  
and the fraction of the site occupied by drug is now given by 
(2). In expression 2, ki is a new constant, including k:. In 
(2) Ii = ki(l - CYcb)-'(l - V i )  
the minimization leading to site-specific binding constants, the 
quantity vi is calculated in terms of the relevant drug binding 
constant Ki and the free drug concentration cf by use of con- 
ventional equilibrium constant expressions. For an isolated 
drug binding site 
vi = K i c f / (  1 + K,tf) (3) 
Thefree drug contribution cf is determined from the total drug 
concentration by the equilibria between the free drug and the 
drug bound to labeled fragment and unlabeled carrier DNA. 
Since the carrier concentration (193 pM) is much larger than 
that of fragment (1 pM), the equilibrium between the drug 
and carrier determines the amounts of free and bound drug 
present in the system, and the concentration of fragment need 
not be known accurately. 
The concentration of strong sites on carrier DNA for lex- 
itropsin (2), c, can be estimated by noting that there are 4 
binding sites for 2 in the 120 base pairs out of a total of 139 
observed on the radiolabeled fragment. If the same ratio of 
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FIGURE 3: Deviation D (eq 5 )  with best value of IKi], Ke,  and K, for 
different assumed values of c,. (a) Netropsin; (b)  lexitropsin. 
binding sites to base pairs obtains for the carrier, the con- 
centration of sites on the carrier would be (4/120)(193 yM)  - 6 yM.  Similarly, and considering only the strong sites for 
netropsin, a value of about (8/120)(193 yM)  - 13 y M  is 
expected for the concentration of strong netropsin sites on the 
carrier. I n  our previous work (Ward et al., 1988a) we in- 
correctly assumed a strong-site concentration of c, = 194 y M  
for netropsin on the carrier DNA. Furthermore, we argued 
that the product Kcc,, where K, is the binding constant toward 
the carrier DNA, and not the value of c, itself, is important 
in determining the amount of drug bound to the carrier. While 
this is sometimes true, we now find that K, and c, behave as 
independent parameters when c, becomes comparable to or 
less than the ligand concentrations used. Thus, the concen- 
tration of strong sites on the carrier, c,, and their average 
binding constant, K,, can be determined from the footprinting 
data derived from the radiolabeled fragment. 
The value of K, will be an average of the strong-site binding 
constants on the carrier and will also depend on the value 
assumed for c, (see below). One cannot directly compare K, 
derived from quantitative footprinting analysis with the binding 
constant obtained by applying a Scatchard analysis to the 
results of optical, filter binding, or phase-partition experiments. 
First, as noted by McGhee and Von Hippel (1 974), Scatchard 
analysis can give binding constants "substantially in error" 
when applied to a substrate possessing overlapping binding 
sites. Second, although the binding constant obtained in this 
way is, like our K,, a weighted average of binding constants 
for different sites, the weighted average in the case of the 
Scatchard analysis differs from the weights entering K, derived 
from footprinting data, thus complicating the comparison 
between the two quantities. 
To see what these weights are in the case of the footprinting 
data, suppose the actual carrier sites C1, C2, etc. have binding 
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FIGURE 4: Van't Hoff plots of the site-specific binding constants for 
netropsin (1). (a) Sites 56 (0); 57 (a and top line); 47 (0 and second 
line); 46 (*). (b) Sites 58 (0), 59 (0). (c) Site 87 (0); carrier (0). 
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FIGURE 5: Van't Hoff plots of the site-specific binding constants for 
lexitropsin (2) for sites 76 (0, solid line), 119 (0, long-dash line), 
106 (A,  medium-dash line), 63 (0, short-dash line). 
constants K,,, Kc2, etc. and concentrations c,, c2, etc., so the 
bound-drug concentration, cb, is actually 
(4a) 
(This assumes carrier sites i do not overlap. If they do, the 
equation is somewhat more complicated.) We write instead 
c b  = CCi KciCf/(I + Kcjcf) 
i 
For small cf, (4a) becomes 
cb = (CciKci)cf 
i 
Thermodynamic Data from DNA Footprints 
and (4b) becomes 
Thus, K, represents (C,ciKJ/c,, for small drug concentrations. 
The equivalence of (4a) and (4b) a t  low values of the total 
drug concentration is another reason for restricting the analysis 
to the earliest parts (low drug) of the footprinting plots. 
A third point to make in connection with the values of K, 
derived from footprinting data with those obtained through 
Scatchard analyses is that in the former case only the earliest 
loading events on the carrier are being examined. Typically, 
the footprinting-derived values of K, are obtained from data 
where the ratio of bound drug to available DNA base pairs, 
r, is small <-0.05. Unfortunately it is this region of the 
Scatchard plot, r of <-0.05, where uncertainties are large 
and an accurate determination of K from the plot is difficult 
to make. Thus, comparisons between K, from footprinting data 
and other values obtained through conventional methods may 
not be straightforward. 
Detrrniination of Binding Constants. After addressing 
exclusion effects due to overlapped sites on DNA, the quan- 
tities I i  may be calculated for each total ligand concentration, 
given values for a, K,, and the Ki. These values are then 
determined as those which minimize 
cb = CcKcCf 
Biochemistry, Vol. 29, No. 26, 1990 6143 
Table I:  Thermodynamic Parameters for Netropsin (1) and 
Lexitropsin (2) at 25 OC 
D = - iij)* 
i j  
(5) 
where I i j  is the experimental spot intensity for site i, propor- 
tional to oligonucleotide concentration, a t  a total drug con- 
centration of cj, and iij is the corresponding calculated spot 
intensity. The search for values that minimize D is carried 
out according to the Simplex search algorithm (Ward et al., 
1988a; Dabrowiak et al., 1989a,b; Dabrowiak & Goodisman, 
1989). Direct knowledge of the free drug concentration is not 
required: its value for any total drug concentration is calcu- 
lated in terms of cj and K,. The analysis assumes noncoop- 
erative independent binding events on the 139-mer. For the 
generally low binding density over the concentration range 
studied this assumption is reasonable. 
In our first quantitative analysis of a footprinting experiment 
(Ward et al., 1988a), we fixed the concentration of strong 
netropsin sites on the calf thymus DNA used as a carrier 
before minimizing D, the deviation between experimental and 
calculated data (eq 5). It is now clear that the value of D 
depends on the value assumed for c, (Figure 3). Although 
D varies little with c, when the latter quantity is large, there 
is a clear minimum for c, of - 10 pM for netropsin (Figure 
3a). If K ,  and c, along with the other constants, are deter- 
mined by minimization of D, the values of the site-specific 
binding constants for netropsin toward the fragment are 
somewhat lower than those earlier published (Ward et al., 
1988a). As is shown in Figure 3b, the value of c, for the 
lexitropsin, as determined by the minimum in D, is - 1.4 pM. 
Once the values of c, for both ligands were determined a t  one 
temperature, 37 "C for 1 and 15 "C for 2, this value was fixed 
for the remaining minimizations at  the various temperatures. 
In view of the modest sensitivity of the individual Ki's to the 
value of c, (Figure 3), this appears to be a valid approximation. 
From analysis of the footprinting experiments at  each tem- 
perature, we get the binding constants Ki toward the individual 
sites on the labeled fragment. These are  shown in Figures 4 
and 5 as a function of temperature. Linear fits of log Ki versus 
1 /T  are also shown. From AGO = -RT In K a t  25 "C and 
d(log D)/d(l/T) = -AH0/2.303R, we get the thermodynamic 
parameters given in Table I. The stated errors in AH" and 
AS" come from the correlation coefficients of the least-square 
fits. We  also obtain a value for K,, the average binding 
AGO AHo A s o  
position sequencea (kJ/mol) (kJ/mol) (J/mol K )  
Netropsin (1) 
46 TTTA -37.7 f 0.4 -18 f 8 65 f 26 
47 TTAT -41.3 f 0.7 -25 f 4 5 4 f  14 
56 TTAA -33.1 f 0.6 25 f 3 195 f IO 
57 TAAA -40.7 f 0.7 -22 f 9 62 f 30 
58 AAAT -41.9 f 0.8 -16 f 12 87 f 40 
59 AATT -40.6 f 0.6 -10 f IO 102 f 32 
89 AAAT -42.6 f 0.3 -12 f 6 103 f 20 
AAAT 
AATA 
AATT 
ATTT 
TTTA 
TTAA 
TTTA 
Lexitropsin (2)b 
63 GCTAACGCAG -26.2 f 0.5 -29.7 f 9.9 -12 f 33 
CGATTGCGTC 
CCGTGGCAC 
GTAGCAGTA 
CCGTGGCAG 
76 G G C A C D  -30.0 f 0.3 -43.6 f 5.3 -46 f 18 
106 CAT-AT -25.3 f 0.7 -61.4 f 13.0 -121 f 44 
119 GGCAC- -29.2 f 0.5 -55.9 f 8.7 -89 f 29 
"Sequence is 5'-3' on the coding (top) strand. bSpecific sequences 
of ligand contact for 2 are not given. However, the most likely contact 
sequence within the entire inhibition region is indicated. The region 
was modeled as a single ligand binding event. 
constant to the strong sites on the carrier D N A  (Figure 4). 
In the case of netropsin, this value is -1 X IO7 M-I, which 
is -2 orders of magnitude higher than those derived by 
Scatchard methods (Zimmer & Wahnert, 1986). However, 
as was earlier stated, direct comparison between the value of 
K, derived from footprinting data and those earlier reported 
may not be possible. The value of K, for the lexitropsin was 
found to be 6.7 X lo6 M-' a t  25 "C. 
Thermodynamic Data. Explaining the thermodynamic data 
is made difficult by the fact that contributions to AGO, AH", 
and AS" can come from at least three sources (Chaires, 1985). 
One includes hydrogen bonding, van der Waals effects, and 
hydrophobic/electrostatic interactions between the drug and 
its DNA binding site. A second source is conformational 
changes that take place within the DNA site or the drug as 
binding occurs. Finally, since both the drug and DNA are 
highly solvated and have associated counterions, water release 
and ion redistribution very likely accompany binding. It is 
not possible to unequivocally determine which factor influences 
which thermodynamic parameter. However, the reduced 
charge of 2 compared to netropsin is probably a major con- 
tributing factor to the lower binding constants and less negative 
AGO for the former compound (Table I). A parallel argument 
can be advanced to explain the lower binding constant of 
distamycin, which is a monocation, compared to netropsin, 
which is a dication (Zimmer & Wahnert, 1986). 
The presence of a 5'-TA-3' sequence in the netropsin binding 
site gives rise to a distortion in the minor groove of DNA 
(Calladine, 1982). This may not only discourage the binding 
of the drug but may also affect the degree of solvation within 
the groove (Drew & Dickerson, 1985; Kennard et al., 1986). 
Without additional study it is not possible to ascertain the 
effects of flanking sequence on the thermodynamic parameters. 
However, the sequence 5'-AAAT-3', which occurs imbedded 
in an A T  tract a t  position 58, has essentially the same ther- 
modynamic parameters as does the isolated site of the same 
sequence a t  89. 
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For netropsin, ASo is positive, as expected for association 
of two solvated species, the drug and DNA, with ordered 
solvent being released from DNA. Negative values of ASQ 
are found for 2, which may reflect the disorderly binding of 
water at G C  sites (Kennard et al., 1986). This water is lib- 
erated from DNA to the more ordered structure of the bulk 
solvent. 
The values for AHo for netropsin are all negative and about 
the same size (from -10 to -25kJ/mol) except for site 56, 
having the sequence 5’-TTAA-3’, which is positive. The 
earlier, direct, calorimetric measurements of AHo by Breslauer 
et al. ( 1988) primarily used poly(dAdT).poly(dAdT), poly- 
(dA).poly(dT) and certain oligonucleotide duplexes as host 
DNA for netropsin. The small oligonucleotide duplex, d- 
(GCGAATTCGC)2, studied calorimetrically, possesses the 
netropsin binding sequence 5’-AATT-3’, which is found at  
position 59 of the 139-mer (Figure I ) .  However, despite the 
fact that the free energy of netropsin binding to this sequence, 
obtained by us (Table I) ,  is similar to that obtained by other 
means (Marky & Breslauer, 1987), our enthalpy of -10 f 
lOkJ/mol is quite different from that obtained via calorimetric 
measurements, -38.9 kJ/mol. It is possible that the restriction 
fragment undergoes a structural change over the temperature 
range of the study and that this is a factor affecting the 
thermodynamic parameters, but this does not appear likely. 
DNase I ,  which is sensitive to DNA structural changes (Drew 
& Travers, 1984), showed no change in its cleavage pattern 
of the 139-mer as a function of temperature. It is also possible 
that the length of DNA is important in the interaction. In  
our experiments, the sequence 5’-AATT-3’ is imbedded in a 
long polymer, while in the earlier calorimetric studies (Bres- 
lauer et al., 1988) it was part of a decamer. Quantitative 
footprinting experiments with actinomycin D using a small 
DNA oligomer as well as the 139-mer have suggested that 
DNA length may affect the binding constant of the anticancer 
drug to DNA (Rehfuss et al., 1990; Dabrowiak & Goodisman, 
1990). Clearly, additional work involving quantitative foot- 
printing methods and other techniques will be necessary to fully 
understand how polymer length, flanking sequences, degree 
of solvation, and other factors influence the thermodynamic 
properties of drug/DNA interactions at  the sequence level. 
As is evident from Table I ,  the errors associated with the 
sites for netropsin are quite large. This appears to be due to 
the number of overlapped netropsin sites on the 139-mer and 
the small (relative to the number of binding constants) number 
of concentration points used in the footprinting titrations, 
giving rise to fewer data points to fit more parameters. Since 
there are no overlaps and fewer parameters to fit,  the errors 
associated with the lexitropsin are generally lower than those 
found for netropsin (Table I ) .  
CONCLUSIONS 
I n  this report we show that, by carrying out multiple 
footprinting experiments a t  a number of different tempera- 
tures, it is possible to obtain the full thermodynamic profile 
of a drug, AGO, AH’, and ASo ,  as a function of sequence on 
polymeric DNA. The technique requires the measurement 
of autoradiographic spot intensities on a DNA sequencing 
autoradiogram. With a parametrized model for the various 
equilibria present in the system, the difference between cal- 
culated and measured intensities is used in a minimization 
approach to derive site-specific drug binding constants and 
other parameters characterizing the system. The temperature 
dependence of the binding constants, given as van’t Hoff plots, 
allows the determination of site-specific enthalpies and en- 
tropies for the drug. I n  the case of netropsin, the enthalpies 
Dabrowiak et al. 
for various sequences on the 139-mer are mostly negative and 
agree in size, but are smaller (less negative) than the few 
sequence-specific enthalpies determined by other means. The 
large negative AHo values observed for the bis(N-methyl- 
imidazole) lexitropsin (2) as compared with netropsin may be 
due to the greater ability of the former compound to hydrogen 
bond to sites located in the minor groove of DNA. 
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Preferential Binding of Daunomycin to 5’*CG and 5’tGC Sequences Revealed 
by Footprinting Titration Experiments? 
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ABSTRACT: Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure 
are  described that identify preferred daunomycin binding sites within the 160 bp tyr T D N A  fragment. 
We  have obtained single-bond resolution a t  65 of the 160 potential binding sites within the tyr T fragment 
and have examined the effect of 0-3.0 N M  total daunomycin concentration on the susceptibility of these 
sites toward digestion by DNase I. Four types of behavior are observed: (i) protection from DNase I cleavage; 
(ii) protection, but only after reaching a critical total daunomycin concentration; (iii) enhanced cleavage; 
(iv) no effect of added drug. Ten sites were identified as the most strongly protected on the basis of the 
magnitude of the reduction of their digestion product band areas in the presence of daunomycin. These 
were identified as the preferred daunomycin binding sites. Seven of these 10 sites are found a t  the end of 
the triplet sequences 5’qGC and 5’iCG, where the notation 4 indicates that either A or T may occup the 
Of the preferred daunomycin binding sites we identify in this study, the sequence 5’qCG is consistent with 
the specificity predicted by the theoretical studies of Chen et al. [Chen, K.-X., Gresh, N., & Pullman, B. 
(1985) J .  Biomol. Struct.  Dyn. 3, 445-4661 and is the very sequence to which daunomycin is observed to 
be bound in two recent X-ray crystallographic studies. Solution studies, theoretical studies, and crystal- 
lographic studies have thus converged to provide a consistent and coherent picture of the sequence preference 
of this important anticancer antibiotic. 
position. The  remaining three strongly protected sites are found a t  the ends of the triplet sequence 5’&$. K 
T h e  cellular target of many clinically useful anticancer 
compounds is thought to be DNA (Gale et al., 1981; Chagas 
& Pullman, 1987). A necessary step toward the rational 
design of new anticancer compounds with enhanced potency 
and selectivity is to characterize the DNA binding specificity 
of these existing compounds of proven clinical utility and to 
elucidate the molecular mechanisms that govern their se- 
quence-selective binding to DNA. It is hoped that this activity 
will produce, ultimately, a set of rules to guide the rational 
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by the National Cancer Institute, Department of Health and Human 
Services, National Science Foundation Grant INT-8521004 (J.B.C.), and 
grants from the Cancer Research Campaign (M.J.W.) .  
OO06-2960/9O/O429-6 145$02.50/0 
design of a new generation of anticancer compounds targeted 
to specific DNA sites. 
With this larger goal in mind, our laboratory has studied 
the interaction of daunomycin with DNA by a variety of 
physical and biochemical methods (Britt et al., 1986; Chaires, 
1983a,b, 1985a,b; Chaires et al., 1982a,b, 1983, 1985, 1987; 
Herrera & Chaires, 1989; Fritzsche et al., 1982, 1987). 
Daunomycin is the prototype anthracycline antibiotic, a class 
of compounds that has well-documented utility in cancer 
chemotherapy (Arcamone, 198 1 ; Crooke & Reich, 1980; 
Remers, 1984). Daunomycin binds to DNA by the process 
of intercalation, and the fundamental aspects of the physical 
chemistry of its binding to DNA have been well characterized 
[for reviews, see Fritzsche and Berg (1987) and Chaires 
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